VAVicente Aguadero

Vicente Aguadero

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Vicente Aguadero has a total of 63 co-authors. Here are the top co-authors by number of shared publications:

  • Elisa Nuez-Zaragoza

    Clinical Laboratory Department Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí (I3PT‐CERCA), Universitat Autònoma de Barcelona Sabadell Barcelona Spain

    5 shared publications
  • Indira Bhambi-Blanco

    Clinical Laboratory Department Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí (I3PT‐CERCA), Universitat Autònoma de Barcelona Sabadell Barcelona Spain

    5 shared publications
  • Mònica Vidal-Pla

    Clinical Laboratory Department Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí (I3PT‐CERCA), Universitat Autònoma de Barcelona Sabadell Barcelona Spain

    5 shared publications
  • Isabel Aparicio-Calvente

    Clinical Laboratory Department Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí (I3PT‐CERCA), Universitat Autònoma de Barcelona Sabadell Barcelona Spain

    3 shared publications
  • Joan Carles Ferreres

    Pathology Department Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí (I3PT‐CERCA), Universitat Autònoma de Barcelona Sabadell Barcelona Spain

    3 shared publications
  • Laia Mas-Maresma

    Internal Medicine Department Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí (I3PT‐CERCA), Universitat Autònoma de Barcelona Sabadell Barcelona Spain

    3 shared publications

Latest Publications

  • Open Access

    A Three‐Step Diagnostic Strategy for Malignant Pleural Effusions

    by Elisa Nuez‐Zaragoza, Vicente Aguadero, Indira Bhambi‐Blanco, Mònica Vidal‐Pla, Isabel Aparicio‐Calvente, M. Rosa Escoda‐Giralt, Joana Gallardo‐Campos, Joan Carles Ferreres, Luis Frisancho, Laia Mas‐Maresma, et al.

    New diagnostic tools, such as high fluorescence cells (HFc) and tumor markers (TMs), have emerged in the quest to accurately diagnose malignant pleural effusion (MPE). This study evaluated the diagnostic performance of the HFc and TMs combination. Hospitalized patients with pleural effusion were recruited at Parc Taulí University Hospital in Sabadell (Spain). Pleural fluid (PF) and serum samples were collected and analyzed in the Clinical Laboratory, and PF samples were sent to the Pathology Department for cytological examination. PF cell counts were determined using an XN‐10 analyzer (Sysmex, Kobe, Japan); TMs (CEA, CA 19.9, CA 15.3, CA 72.4, and CYFRA 21.1) were assessed using Cobas e801 (Roche Diagnostics, Mannheim, Germany). An MPE diagnosis was made based on positive cytology and/or positive pleural biopsy. A diagnostic algorithm was developed to detect MPE starting with an initial HFc screening, followed by TM determination with specific cutoffs depending on fluid type. The study included 300 pleural effusions from 209 patients. The algorithm had a sensitivity of 68% and a negative predictive value of 93%; its specificity and positive predictive value were both 100%. When combined with cytology, the sensitivity of the algorithm increased to 85%, and its negative predictive value to 96%. Our algorithm exhibited promising diagnostic performance and could serve as a non‐invasive tool for MPE detection. HFc screening helps identify potential MPE cases, and TM assessment, with its high specificity, contributes to MPE confirmation. Furthermore, establishing different TM cutoffs based on fluid type increases sensitivity without reducing specificity by introducing false positives.

  • Open Access

    Determination of HE4 in pleural fluid and ratio: considerations and diagnostic performance for malignant pleural effusion

    by Elisa Nuez-Zaragoza, Indira Bhambi-Blanco, Isabel Aparicio-Calvente, Mònica Vidal-Pla, M. Rosa Escoda-Giralt, Joana Gallardo-Campos, Joan C. Ferreres, Luis Frisancho, Laia Mas-Maresma, Patricia Aguilera-Fernández, et al.

    Objectives: The objectives of this study included assessing the diagnostic performance of HE4 in malignant pleural effusions (MPEs) and identifying the benign etiologies associated with higher HE4 concentrations. Methods: The study involved patients with pleural effusion (PE) treated at Part Taulí University Hospital. PE and serum samples were collected and analyzed. Diagnosis of MPE was established by the presence of a positive cytology and/or positive pleural biopsy. HE4 concentrations in LP and serum – among other parameters – were measured on an ECLIA-Cobas e801 (Roche Diagnostics) analyzer. Subsequently, pleural fluid to serum HE4 ratio (PF/serum HE4 ratio) was calculated. Patients were assigned to different groups according to final diagnosis, transudate vs. exudate, MPE etiology and estimated glomerular filtration rate (eGFR). An evaluation was performed of the diagnostic performance of HE4 for MPE. Results: A total of 253 PF and serum samples were included. In patients with benign pleural effusion (BPE), transudates contained higher levels of HE4, as compared to exudates. The highest PF-HE4 concentrations and ratios were observed in MPEs, especially in patients with non-small cell lung cancer + ovarian cancer. The cut-off values established showed a sensitivity of 16.7 % (PF-HE4) and 12.1 % (ratio), with a 100 % specificity, respectively. Following cut-off adjustment, higher sensitivity values were observed in patients with an eGFR ≥ 30 mL/min/1.73 m 2 . Conclusions: Elevated HE4 concentrations may support MPE diagnosis and predict histology. Transudates contain elevated levels of HE4 and lower PF/serum-HE4 ratios. In the investigation of solid neoplasms, different serum HE4 cut-off values should be used for patients with PE, heart failure, cirrhosis or renal insufficiency.

  • Utility of the combination of high fluorescence cells and tumor markers for the diagnosis of malignant pleural effusions

    by Elisa Nuez-Zaragoza, Indira Bhambi-Blanco, Mònica Vidal-Pla, Isabel Aparicio-Calvente, M. Rosa Escoda-Giralt, Joana Gallardo-Campos, Joan C. Ferreres, Luis Frisancho, Laia Mas-Maresma, Patricia Aguilera-Fernández, et al.


  • Open Access

    Los análisis de orina en el diagnóstico de las gammapatías monoclonales: puntos de corte

    by Mònica Vidal-Pla, Elisa Nuez-Zaragoza, Indira Bhambi, Vicente Aguadero

    Resumen: Objetivos: Las pruebas de laboratorio resultan cruciales en el diagnóstico de las gammapatías monoclonales. La última actualización de la guía del Grupo Internacional de Trabajo sobre el Mieloma (IMWG) para el diagnóstico de gammapatías monoclonales ha suscitado cierto debate sobre la pertinencia de realizar análisis de orina en el diagnóstico de estas patologías. Métodos: Realizamos un estudio retrospectivo con datos de 132 pacientes con detección reciente de componente monoclonal (CM) en suero. Se dividió a los pacientes en dos grupos, en función de la presencia o ausencia del componente monoclonal (CM) en la orina. A continuación, se recogieron diversas variables para analizar posibles diferencias entre los grupos. Resultados: El objetivo del presente estudio era establecer un punto de corte para la concentración de CM en suero por debajo del cual no fuese necesario realizar un análisis de orina en el diagnóstico inicial en el laboratorio. Los resultados muestran que, cuando la concentración de CM en suero es ≤3,5 g/L y la eGFR es >30 mL/min/1,73m 2 (sensibilidad (S): 100 %, especifidad (Sp): 49 %, valor predictivo negativo (VPN): 100 %), la probabilidad de hallar CM en orina es mínima. Los pacientes con CM con cadena pesada alfa tienen mayor probabilidad de presentar CM en la orina. De este modo, cuando la cadena pesada el CM es gamma o mu, el punto de corte en suero se puede elevar a ≤4,9 g/L (S: 97 %, Sp: 52 %, VPN: 98 %). Conclusiones: El empleo de estos dos puntos de corte en la detección inicial de un CM podría evitar la realización innecesaria de un número considerable de análisis de orina, optimizando así el consumo de recursos analíticos y sanitarios.


  • Open Access

    Urine analysis in monoclonal gammopathies at diagnosis: settling cut-off values

    by Mònica Vidal-Pla, Elisa Nuez-Zaragoza, Indira Bhambi, Vicente Aguadero

    Objectives: Laboratory testing has an extensive role in the diagnosis of monoclonal gammopathies. Since the last updates of the International Myeloma Working Group (IMWG) guidelines for the diagnosis of monoclonal gammopathies, debate has arisen as to whether urine analysis remains relevant for the diagnosis of these entities. Methods: We carried out a retrospective study with data from 132 patients with a newly diagnosed serum M-protein. Patients were divided into two groups depending on the presence of M-protein in urine and different variables were recorded and statistically compared between groups. Results: The aim of the study was to find a serum M-protein cut-off value under which urine analysis could be avoided in the first laboratory diagnosis. The results show that when the concentration of serum M-protein is ≤3.5 g/L and eGFR is >30 mL/min/1.73 m 2 (sensitivity (S): 100 %, specificity (Sp): 49 %, negative-predictive value (NPV): 100 %) the probability of finding M-protein in urine is negligible. Patients with alpha heavy chain have a higher probability of having M-protein in urine. Thus, when the heavy chain of the M-protein is gamma or mu, serum cut-off value can be raised up to ≤4.9 g/L (S: 97 %, Sp: 52 %, NPV: 98 %). Conclusions: Settling these two cut-off values when a new M-protein is discovered could avoid a significant number of urine analyses, optimizing laboratory and healthcare resources.


  • Reply to Luksic et al. Clin Chem Lab Med 2018;56(4):574–581

    by Mònica Vidal-Pla, Paula San-José, Vicente Aguadero, Ruth Cano-Corres, Patricia García-Humia, Basma Swadak, Eugenio Berlanga-Escalera

    Article Reply to Luksic et al. Clin Chem Lab Med 2018;56(4):574–581 was published on November 1, 2019 in the journal Clinical Chemistry and Laboratory Medicine (CCLM) (volume 57, issue 11).

  • Papel central del laboratorio en el diagnóstico de un caso de infiltración de sistema nervioso central por mieloma múltiple refractario

    by Miguel Aliste, Alex Larruzea, Vicente Aguadero, Luz Muñoz, María Elena Ramila, Eugenio Berlanga

  • Open Access

    Gamma heavy-chain disease accompanied with follicular lymphoma: a case report

    by Paula San-José, Vicente Aguadero, Granada Perea, Meritxell Estrada, Eugenio Berlanga

    Heavy chain diseases (HCD) are B-cell lymphoprolipherative disorders characterized by the production of monoclonal heavy chains without associated light chains. Some cases of gamma-HCD (γ-HCD) are concurrent with other lymphoid neoplasm. The monoclonal component is not always detectable by serum electrophoresis, and often an immunofixation procedure is necessary to detect this component. Prognosis is variable, and no established guidelines for follow-up are available. We describe a case of a challenging diagnosis of γ-HCD due to the absence of clinical signs frequently reported in the disease (anaemia and palatal oedema among others). Haematological malignancy was the first suspicion but bone marrow examination was negative. In addition, the presence of an autoimmune bicytopenia and a Klinefelter syndrome complicated the clinical context of the patient. A thoracoabdominal computed tomography reported many small adenopathies whose pathological and immunohystochemical study revealed a follicular lymphoma. Shortly after, serum inmunofixation secondary to an abnormal electrophoretic pattern revealed a gamma paraprotein without light chains. Eventually, γ-HCD in association with follicular lymphoma was the final diagnosis. This is the first case reporting this association.